Broadening the horizons for yellow fever: New uses for an old vaccine

Journal of Experimental Medicine

Volumn 201, Issue 2, 2005, Pages 165-168

  Van Epps, Heather L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN; YELLOW FEVER VACCINE;

DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

FLAVIVIRUS INFECTIONS; HUMANS; SEQUENCE ANALYSIS, PROTEIN; VIRAL PROTEINS; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 13244275192     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20042565     Document Type: Review

References (13)

1. Lefeuvre, A., P. Marianneau, and V. Deubel. 2004. Current assessment of yellow fever and yellow fever vaccine. Curr. Infect. Dis. Rep. 6:96-104.
2. Theiler, M., and H.H. Smith. 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:787-800.
3. Monath, T.P. 2004. Yellow fever: an update. Lancet Infect. Dis. 1:11-20.
4. Reinhardt, B., R. Jaspert, M. Niedrig, C. Kostner and J. L'age-Stehr. 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56:159-167.
5. Co, M.D.T., M. Terajima, J. Cruz, F.A. Ennis, and A.L. Rothman. 2002. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on non-structural proteins NS1, NS2b, NK3 and the structural protein E. Virology. 293:151-163.
6. Rice, C.M., A. Grakoui, R. Galler, and T.J. Chambers. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:285-296.
7. Bray, M., and C.J. Lai. 1991. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. USA. 88:10342-10346.
8. Chambers, T.J., A. Nestorowicz, P.W. Mason, and C.M. Rice. 1999. Yellow fever/ Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:3095-3101.
9. Bonaldo, M.C., R.C. Garratt, P.S. Caufour, M.S. Freire, M.M. Rodrigues, R.S. Nussenzweig, and R. Galler. 2002. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J. Mol. Biol. 315:873-885.
10. McAllister, A., A.E. Arbetman, S. Mandl, C. Pena-Rossi, and R. Andino. 2000. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J. Virol. 74:9197-9205.
11. Tao, D., G. Barba-Spaeth, U. Rai, V. Nussenzweig, C.M. Rice, and R.S. Nussenzweig. 2005. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J. Exp. Med. 201:201-209.
12. Bojang, K.A., P.J. Milligan, M. Pinder, L. Vigneron, A. Alloueche, K.E. Kester, W.R. Ballou, D.J. Conway, W.H. Reece, P. Gothard, et al. 2004. Efficacy of RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: a randomized controlled trial. Lancet. 364:1411-1420.
13. Mueller, A., M. Labaied, S.H.I. Kappe, and K. Matuschewski. 2004. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 10.1038/nature03188.